Provided by Tiger Trade Technology Pte. Ltd.

Precision Biosciences Inc

3.80
+0.23006.44%
Post-market: 3.890.0870+2.29%19:41 EST
Volume:91.54K
Turnover:344.94K
Market Cap:91.47M
PE:-0.46
High:3.83
Open:3.61
Low:3.58
Close:3.57
52wk High:8.82
52wk Low:3.53
Shares:24.07M
Float Shares:22.82M
Volume Ratio:0.51
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.3225
EPS(LYR):1.04
ROE:-205.16%
ROA:-45.34%
PB:5.50
PE(LYR):3.65

Loading ...

JonesTrading Keeps Their Buy Rating on Precision BioSciences (DTIL)

TIPRANKS
·
Jan 23

Empery Asset Management Lp Reports 9.99% Passive Stake in Precision BioSciences as of Dec 31, 2025 - SEC Filing

THOMSON REUTERS
·
Jan 23

Precision BioSciences Announces 2026 Strategic Plan Focused on Advancing Clinical-Stage PBGENE-HBV and PBGENE-DMD Programs, Initiating DMD Clinical Trials, and Maintaining Cash Runway Through 2028

Reuters
·
Jan 12

BRIEF-Precision Biosciences Inc Files For Mixed Shelf Of Up To $250 Million - SEC Filing

Reuters
·
Dec 30, 2025

Precision BioSciences Inc: Files for Mixed Shelf of up to $250 Mln - SEC Filing

THOMSON REUTERS
·
Dec 30, 2025

Precision BioSciences Grants Inducement RSUs to New Employee

Reuters
·
Dec 23, 2025

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Dec 23, 2025

Director Geno J. Germano Acquires Common Shares of Precision BioSciences Inc

Reuters
·
Dec 17, 2025

Director Melinda Brown Acquires Common Shares of Precision BioSciences Inc

Reuters
·
Dec 17, 2025

H.C. Wainwright Keeps Their Buy Rating on Precision BioSciences (DTIL)

TIPRANKS
·
Nov 21, 2025

Precision BioSciences Unveils Positive Phase 1 ELIMINATE-B Trial Results for PBGENE-HBV

Reuters
·
Nov 19, 2025

Precision BioSciences Announces Presentation of Clinical Data From the Eliminate-B Trial at Hep-Dart 2025

THOMSON REUTERS
·
Nov 19, 2025

Precision BioSciences announces $75M offering of common stock, warrants

TIPRANKS
·
Nov 11, 2025

BRIEF-Precision BioSciences Announces $75 Million Offering Of Common Stock, Pre-Funded Warrants And Warrants

Reuters
·
Nov 11, 2025

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

THOMSON REUTERS
·
Nov 11, 2025

Precision BioSciences Reports Positive Phase 1 Results for Gene Editing Therapy in Chronic Hepatitis B

Reuters
·
Nov 11, 2025

Precision BioSciences trading halted, news pending

TIPRANKS
·
Nov 11, 2025

Precision BioSciences Q3 revenue falls sharply

Reuters
·
Nov 03, 2025

Precision BioSciences reports third quarter 2025 revenue of less than $0.1 million and research and development expenses of $13.4 million

Reuters
·
Nov 03, 2025

Precision BioSciences Q3 EPS $(1.84) Misses $(1.34) Estimate, Sales $13.000K Miss $5.400M Estimate

Benzinga
·
Nov 03, 2025